Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BVT 74316

Next Previous
Search
Drug Profile

BVT 74316

Alternative Names: BVT.74316; BVT74316

Latest Information Update: 28 May 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biovitrum
  • Developer Proximagen
  • Class Anorectics; Benzofurans; Obesity therapies
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Obesity(In volunteers) in Sweden (PO, Tablet)
  • 14 Aug 2012 Proximagen has been acquired by Upsher-Smith
  • 23 Nov 2009 Proximagen Neuroscience acquires BVT 74316 from Biovitrum

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top